PLURI
LIVE

Serial Number

79397427

Owner

PLURI BIOTECH LTD

Attorney

Alexander Lazouski

Filing Date

Nov 19, 2023

Add to watchlist:

No watchlists yet
View on USPTO

PLURI Trademark

Serial Number: 79397427

PLURI is a trademark filed by PLURI BIOTECH LTD on November 19, 2023. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

PLURI BIOTECH LTD (4 trademarks)

Matam 20

Entity Type: 99

Trademark Details

Filing Date

November 19, 2023

Registration Date

Not Registered

Goods & Services

Cells, their extracts and components and biological preparations intended for medical and clinical use for the treatment of cardiovascular diseases, Critical Limb Ischemia (CLI), muscle regeneration, Acute Radiation Syndrome (ARS), Delayed Effects of Acute Radiation Exposure (DEARE), hematological deficiencies, and pathogenic infectious; bioengineered cells and bioengineered tissue for medical and clinical use for the treatment of cancer; bioengineered cells for use in immunotherapies for treatment of cancer (solid tumors), pathogenic infectious diseases; bioengineered human T cells for medical and clinical use; human cells from placentas for medical and clinical use; dietary supplements based on human cells from placentas for cosmetic and aesthetic use; dietary supplements and medical preparations based on human cells from placentas for use in prevention of hair loss; isolated plant cells, their extracts and components being plant extracts, other than essential oils, for medical and clinical use; isolated and cultivated adherent cells from placenta tissue for medical and clinical use; isolated and cultivated adherent stromal cells derived from placentas of multiple donors for medical and clinical use; ; isolated and cultivated plant cells, their extracts and components being plant extracts, other than essential oils, for medical and clinical use and preparations containing the same for the treatment of inflammatory skin conditions, skin regeneration following burns and/or environmental damage, wound healing, anti-inflammatory processes (e.g., arthritis), maintaining and supporting gut health, boost immunity, and improve general energy levels.

Scientific and technological services, namely, scientific research relating to isolation and culturing of animal cells and plant cells and to animal and plant tissues isolation and culturing, to biological preparations intended for medical, clinical, and scientific use of cultured cells and their extracts, to bioengineered cells and tissues, to bioengineered cells for use in immunotherapy for cancer and other infectious diseases, to bioengineered human T cells, to isolated and cultivated human and animal placentas cells, to isolated plant cells and their extracts, to isolated and cultivated adherent cells from placenta tissue, to isolated and cultivated adherent stromal cells derived from placentas of multiple donors, to isolated and cultivated mammal cells, their extracts and preparations containing them, to isolated and cultivated fish cells and sea food cells and preparations containing the same, to isolated and cultivated plant cells and their extracts and preparations containing the same, to research, development and testing services in the fields of mass production of animal and plant cells, and to research, development and testing services in the fields of large scale production of various cells in bioreactors

Biological preparations for use in industry and science; bioengineered cells for use in industry and science; bioengineered human T cells for use in industry and science; biological tissue, namely, human and animal cells from placentas for use in industry and science; biological tissue, namely, human and animal cells from placentas for use in the manufacture of cosmetic and aesthetic products; biological tissue, namely, human and animal cells from placentas for use in manufacturing biological cosmetic preparations for prevention of hair loss; isolated plant cells, their extracts, and components being botanical extracts, other than essential oils, for use in industry and science; biological tissue, namely, isolated and cultivated adherent cells from placenta tissue for use industry and science; biological tissue, namely, isolated and cultivated adherent stromal cells derived from placentas of multiple donors for use in industry and science; biological tissue, namely, isolated and cultivated mammal cells, their extracts and components for use in industrial manufacture of foodstuffs; biological tissue, namely, isolated and cultivated fish cells and sea food being marine animal cells for use in industrial manufacture of foodstuffs; biological tissue, namely, isolated and cultivated plant cells and their extracts, other than essential oils, for use in industrial manufacture of foodstuffs

Filing History

SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
May 30, 2026 RCCK
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Nov 30, 2025 OPNX
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Nov 20, 2025 RCSC
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Nov 12, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Nov 12, 2025 OPNR
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
May 19, 2025 GNS3
LETTER OF SUSPENSION E-MAILED
May 19, 2025 GNSL
SUSPENSION LETTER WRITTEN
May 19, 2025 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 14, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 14, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 14, 2025 TROA
NOTICE OF REVIVAL - E-MAILED
Apr 14, 2025 NREV
PETITION TO REVIVE-GRANTED
Apr 14, 2025 PETG
TEAS PETITION TO REVIVE RECEIVED
Apr 14, 2025 PROA
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Feb 12, 2025 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Feb 12, 2025 ABN2
REFUSAL PROCESSED BY IB
Aug 18, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jul 30, 2024 RFCS
REFUSAL PROCESSED BY MPU
Jul 29, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jul 2, 2024 RFCR
NON-FINAL ACTION WRITTEN
Jul 1, 2024 CNRT
ASSIGNED TO EXAMINER
Jun 24, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Jun 20, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 20, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jun 13, 2024 REPR